FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2494990149> ?p ?o ?g. }

• W2494990149 abstract "Current adjuvant therapeutic options for the treatment of Glioblastoma (GBM) are often determined by limited histological information. Additionally, most GBM clinical trials for targeted chemotherapeutic agents do not distinguish the genetic mutational tumor profiles of the patients recruited and have failed to reach successful treatment endpoints. The New York Genome Center (NYGC) has undertaken a glioblastoma clinical sequencing outcome pilot study to better determine personal treatment options for patients with GBM using integrated genomic data. During the initial phase of this study for 2015 NYGC has performed whole genome sequencing (WGS) on 10 primary GBM tumor-normal pairs, analyzed each patient9s tumor for single nucleotide variants, structural variants and copy number alterations. In addition RNA sequencing and a DNA methylation assay were also performed on several of the patients. The patient9s genomic profile was then compared to a database of known targeted therapeutic approaches. A final tumor board composed of NYGC scientists, GBM consortium scientists and treating oncologists then reviewed all data prior to identifying a final therapeutic strategy. Data from the first 10 patients revealed RB1 variants to be predominant in half of the patients. SNV9s in NF1 or PIK3R1 were also discovered in 4 out of 10 samples. Remaining lower frequency variants occurred in TP53, PDGFRA, PTEN, PIK3CA, ERBB3, SMO, STAG2, ACVR1, NFKB1 and JAK3. Analysis of copy number alterations resulted in 8 of 10 patients containing the characteristic chromosome 7 amplification combined with chromosome 10 deletion, affecting EGFR and PTEN, respectively. Extreme amplification with potential double minute structural variation of EGFR containing the A289V mutation was observed in 2 of 10 samples. Two samples contained a potentially targetable over-amplification of the PDGFRA/KIT/KDR chromosome 4 locus. Predominant deletions resided in CDKN2A, ESR2, PTEN and FLT3. Hemizygous deletions of RB1 combined with RB1 nonsense or missense variants were observed in 4 samples. To date, RNA sequencing was performed on 5 patient samples. Most strikingly the combination of DNA and RNA sequencing revealed the presence of a putative activating MET exon skipping event in the extracellular domain. This MET variant was considered as a potential targetable variant. Therapeutic options resulting from WGS genomic profiles were the PI3K inhibitor BKM120 (60%), half of these had an additional aberration in MET and were recommended for the combinatorial trial NCT01870726. Drug recommendations for the treatment of GBM based on specific N = 1 patient genomic profiles were also made for nilotinib, vismodegib and palbociclib. Here, we present the first phase of the NYGC GBM clinical outcome study demonstrating how patient WGS information can provide more precise therapeutic options in the treatment of glioblastoma. Citation Format: Kazimierz O. Wrzeszczynski, Nicolas Robine, Vladimir Vacic, Anne-Katrin Emde, Bo-Juen Chen, Will Liao, Kanika Arora, Minita Shah, Ewa A. Grabowska, Vanessa Felice, Esra Dikoglu, Catherine Reeves, Mayu Frank, Vaidehi Jobanputra, Michael C. Zody, Toby Bloom, Robert B. Darnell. NYGC glioblastoma clinical outcomes pilot study: Discovering therapeutic potential in glioblastoma through integrative genomics. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4497." @default.
• W2494990149 created "2016-08-23" @default.
• W2494990149 creator A5001305218 @default.
• W2494990149 creator A5008336744 @default.
• W2494990149 creator A5012795135 @default.
• W2494990149 creator A5019028099 @default.
• W2494990149 creator A5024606831 @default.
• W2494990149 creator A5024689543 @default.
• W2494990149 creator A5026374847 @default.
• W2494990149 creator A5027987031 @default.
• W2494990149 creator A5028787355 @default.
• W2494990149 creator A5033234534 @default.
• W2494990149 creator A5035034609 @default.
• W2494990149 creator A5038698652 @default.
• W2494990149 creator A5054793364 @default.
• W2494990149 creator A5085002780 @default.
• W2494990149 creator A5085972715 @default.
• W2494990149 creator A5088699250 @default.
• W2494990149 creator A5090483373 @default.
• W2494990149 date "2016-07-15" @default.
• W2494990149 modified "2023-09-27" @default.
• W2494990149 title "Abstract 4497: NYGC glioblastoma clinical outcomes pilot study: Discovering therapeutic potential in glioblastoma through integrative genomics" @default.
• W2494990149 doi "https://doi.org/10.1158/1538-7445.am2016-4497" @default.
• W2494990149 hasPublicationYear "2016" @default.
• W2494990149 type Work @default.
• W2494990149 sameAs 2494990149 @default.
• W2494990149 citedByCount "0" @default.
• W2494990149 crossrefType "proceedings-article" @default.
• W2494990149 hasAuthorship W2494990149A5001305218 @default.
• W2494990149 hasAuthorship W2494990149A5008336744 @default.
• W2494990149 hasAuthorship W2494990149A5012795135 @default.
• W2494990149 hasAuthorship W2494990149A5019028099 @default.
• W2494990149 hasAuthorship W2494990149A5024606831 @default.
• W2494990149 hasAuthorship W2494990149A5024689543 @default.
• W2494990149 hasAuthorship W2494990149A5026374847 @default.
• W2494990149 hasAuthorship W2494990149A5027987031 @default.
• W2494990149 hasAuthorship W2494990149A5028787355 @default.
• W2494990149 hasAuthorship W2494990149A5033234534 @default.
• W2494990149 hasAuthorship W2494990149A5035034609 @default.
• W2494990149 hasAuthorship W2494990149A5038698652 @default.
• W2494990149 hasAuthorship W2494990149A5054793364 @default.
• W2494990149 hasAuthorship W2494990149A5085002780 @default.
• W2494990149 hasAuthorship W2494990149A5085972715 @default.
• W2494990149 hasAuthorship W2494990149A5088699250 @default.
• W2494990149 hasAuthorship W2494990149A5090483373 @default.
• W2494990149 hasConcept C104317684 @default.
• W2494990149 hasConcept C120821319 @default.
• W2494990149 hasConcept C121608353 @default.
• W2494990149 hasConcept C126322002 @default.
• W2494990149 hasConcept C141231307 @default.
• W2494990149 hasConcept C143998085 @default.
• W2494990149 hasConcept C16930146 @default.
• W2494990149 hasConcept C190283241 @default.
• W2494990149 hasConcept C2775922572 @default.
• W2494990149 hasConcept C2776194525 @default.
• W2494990149 hasConcept C2777609662 @default.
• W2494990149 hasConcept C2780265364 @default.
• W2494990149 hasConcept C37307934 @default.
• W2494990149 hasConcept C502942594 @default.
• W2494990149 hasConcept C54355233 @default.
• W2494990149 hasConcept C71924100 @default.
• W2494990149 hasConcept C86554907 @default.
• W2494990149 hasConcept C86803240 @default.
• W2494990149 hasConceptScore W2494990149C104317684 @default.
• W2494990149 hasConceptScore W2494990149C120821319 @default.
• W2494990149 hasConceptScore W2494990149C121608353 @default.
• W2494990149 hasConceptScore W2494990149C126322002 @default.
• W2494990149 hasConceptScore W2494990149C141231307 @default.
• W2494990149 hasConceptScore W2494990149C143998085 @default.
• W2494990149 hasConceptScore W2494990149C16930146 @default.
• W2494990149 hasConceptScore W2494990149C190283241 @default.
• W2494990149 hasConceptScore W2494990149C2775922572 @default.
• W2494990149 hasConceptScore W2494990149C2776194525 @default.
• W2494990149 hasConceptScore W2494990149C2777609662 @default.
• W2494990149 hasConceptScore W2494990149C2780265364 @default.
• W2494990149 hasConceptScore W2494990149C37307934 @default.
• W2494990149 hasConceptScore W2494990149C502942594 @default.
• W2494990149 hasConceptScore W2494990149C54355233 @default.
• W2494990149 hasConceptScore W2494990149C71924100 @default.
• W2494990149 hasConceptScore W2494990149C86554907 @default.
• W2494990149 hasConceptScore W2494990149C86803240 @default.
• W2494990149 hasLocation W24949901491 @default.
• W2494990149 hasOpenAccess W2494990149 @default.
• W2494990149 hasPrimaryLocation W24949901491 @default.
• W2494990149 hasRelatedWork W1988260598 @default.
• W2494990149 hasRelatedWork W2011565200 @default.
• W2494990149 hasRelatedWork W2051686304 @default.
• W2494990149 hasRelatedWork W2078092602 @default.
• W2494990149 hasRelatedWork W2312474692 @default.
• W2494990149 hasRelatedWork W2398446374 @default.
• W2494990149 hasRelatedWork W2408239245 @default.
• W2494990149 hasRelatedWork W2480032596 @default.
• W2494990149 hasRelatedWork W2505231112 @default.
• W2494990149 hasRelatedWork W2519134096 @default.
• W2494990149 hasRelatedWork W2564149473 @default.
• W2494990149 hasRelatedWork W2766384413 @default.
• W2494990149 hasRelatedWork W2808401524 @default.
• W2494990149 hasRelatedWork W2887025041 @default.
• W2494990149 hasRelatedWork W2913770589 @default.
• W2494990149 hasRelatedWork W2969402360 @default.

• next